RT Journal Article
SR Electronic
T1 Characterisation of Acute Kidney Injury in Critically Ill Patients with Severe Coronavirus Disease-2019 (COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20069872
DO 10.1101/2020.05.06.20069872
A1 Rubin, Sébastien
A1 Orieux, Arthur
A1 Prevel, Renaud
A1 Garric, Antoine
A1 Bats, Marie-Lise
A1 Dabernat, Sandrine
A1 Camou, Fabrice
A1 Guisset, Olivier
A1 Issa, Nahema
A1 Mourissoux, Gaelle
A1 Dewitte, Antoine
A1 Joannes-Boyau, Olivier
A1 Fleureau, Catherine
A1 Rozé, Hadrien
A1 Carrié, Cédric
A1 Petit, Laurent
A1 Clouzeau, Benjamin
A1 Sazio, Charline
A1 Bui, Hoang-Nam
A1 Pillet, Odile
A1 Rigothier, Claire
A1 Vargas, Frederic
A1 Combe, Christian
A1 Gruson, Didier
A1 Boyer, Alexandre
YR 2020
UL http://medrxiv.org/content/early/2020/05/10/2020.05.06.20069872.abstract
AB Background COVID-19-associated acute kidney injury frequency, severity and characterisation in critically ill patients has not been reported.Methods Single-center cohort performed from March 3, 2020, to April 14, 2020 in 4 intensive care units in Bordeaux University Hospital, France. All patients with COVID19 and pulmonary severity criteria were included. AKI was defined using KDIGO criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterisation (transient vs. persistent acute kidney injury; proteinuria, hematuria and glycosuria), and short-term outcomes was evaluated.Results 71 patients were included, with basal serum creatinine of 69 ± 21 µmol/L. At admission, AKI was present in 8/71 (11%) patients. Median follow-up was 17 [12–23] days. AKI developed in a total of 57/71 (80%) patients with 35% Stage 1, 35% Stage 2, and 30% Stage 3 acute kidney injury; 10/57 (18%) required renal replacement therapy. Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median urine protein/creatinine of 82 [54–140] (mg/mmol) with an albuminuria/proteinuria ratio of 0.23 ± 20 indicating predominant tubulo-interstitial injury. Only 2 (4%) patients had glycosuria. At Day 7 onset of after AKI, six (11%) patients remained dependent on renal replacement therapy, nine (16%) had SCr > 200 µmol/L, and four (7%) died. Day 7 and day 14 renal recovery occurred in 28% and 52 % respectively.Conclusion COVID-19-associated AKI is frequent, persistent severe and characterised by an almost exclusive tubulo-interstitial injury without glycosuria.Competing Interest StatementSebastien Rubin discloses support by Sanofi. Alexandre Boyer discloses support by Gilead and Basilea. Olivier Joannes-Boyau is consultant for Baxter and BBraun. Arthur Orieux, Renaud Prevel, Antoine Garric, Marie-Lise Bats, Sandrine Dabernat, Nahema Issa, Gaelle Mourrissoux, Fabrice Camou, Olivier Guisset, Catherine Fleureau, Hadrien Rozé, Cédric Carrié, Laurent Petit, Benjamin Clouzeau, Charline Sazio, Hoang-Nam Bui, Odile Pillet, Frederic Vargas, Claire Rigothier, Christian Combe, Antoine Dewitte, Matthieu Biais, Didier Gruson disclose no conflict of interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A